Projet ISOBIOTICS (Horizon Europe, appel à projets 2021)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : SIGNED

Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities entering clinical trials reaches the market (1 on 16 for chemical drugs). Consequently, 15 on 24 top blockbuster drugs were biotherapeutics in 2020 (world-market share of about 40% of $175 billion of revenue per year). In order to reduce the immunogenicity of biodrugs, to overcome their fragility and to increase their capacity to reach quickly and massively their target, reduced-size biologics are extensively developed. However, radiolabeling of large molecules by grafting bifunctional chelating agents which do not alter significantly their biological activity is thus no longer possible with smaller biodrugs. It is therefore of paramount importance to devise new radiolabeling approaches carried out on tiny quantities in aqueous media and very soft conditions. It is also crucial to train a new generation of radiochemists in order to implement these methods and to meet the needs of the European industry. ISOBIOTICS ambitions: 1) to develop new chemically-benign strategies for the last-stage radiolabeling of large peptides, small/medium-size proteins, oligonucleotides and analogs with deuterium, tritium and carbon-14 (preclinical and phase 0 clinical evaluation), and fluorine-18 (phase I-III clinical trials); 2) to educate a new generation of young talented PhD students specialized in the radiolabeling of biologics through a combination of interdisciplinary lab research, transdisciplinary and intersectorial secondments, technical taught courses, scientific lectures and complementary skills workshops; 3) to ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS outputs in order to maximize the project’s impact and radiance; 4) to secure the students employment and the sustainability of training structures.

Mots clés : biological drugs, peptide, protein, antibody fragment, oligonucleotide, radiolabeling, deuterium, tritium, carbon 14, fluorine 18, drug innovation, therapeutics, diagnostics, theranostics, imaging

Participants :
- Université d'Aarhus (Danemark) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Cambridge (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Louis-et-Maximilien de Munich (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 260539.2 €
- Institut Karolinska (Suède) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Lisbonne (Portugal) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Sanofi (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 521078.4 €
- Commissariat à l’énergie atomique et aux énergies alternatives (France) — Coordinator, beneficiary, Recherche, subvention : 848080.8 €
- Leibniz-Gemeinschaft (Allemagne) — Partner, associated partner, Recherche, subvention : 0.0 €
- Rosalind Franklin Institute (Royaume-Uni) — Partner, associated partner, Recherche, subvention : 0.0 €
- Gulbenkian Institute for Molecular Medicine (Portugal) — Partner, beneficiary, Recherche, subvention : 486806.4 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 587419.2 €
- Université Paris-Saclay (France) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Conseil supérieur de la recherche scientifique (Espagne) — Partner, associated partner, Recherche, subvention : 0.0 €
- Université Raymond-Lulle (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Oxford (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- AstraZeneca (United Kingdom) (Royaume-Uni) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €